Literature DB >> 31660010

Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers.

Louis Kuritzky1, Timothy S Reid2, Carol H Wysham3.   

Abstract

IN BRIEF Basal insulin therapy is well established for glycemic control in patients with diabetes but often is not optimally implemented, leading to poor clinical outcomes and adherence. Primary care providers can and should work together with other members of the diabetes care team to allow for effective titration of basal insulin that involves patients and their caregivers. Adequate guidance and monitoring during the titration process can minimize some of the adverse effects caused by basal insulin administration, while improving glycemic control in a timely manner.
© 2019 by the American Diabetes Association.

Entities:  

Year:  2019        PMID: 31660010      PMCID: PMC6794223          DOI: 10.2337/cd18-0091

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN: 0891-8929


  45 in total

1.  Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes.

Authors:  Francesca Porcellati; Paola Lucidi; Patrizia Cioli; Paola Candeloro; Anna Marinelli Andreoli; Stefania Marzotti; Maura Ambrogi; Geremia B Bolli; Carmine G Fanelli
Journal:  Diabetes Care       Date:  2014-12-18       Impact factor: 19.112

2.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez
Journal:  Endocr Pract       Date:  2018-01-17       Impact factor: 3.443

Review 3.  Insulin therapy in type 2 diabetes mellitus: a practical approach for primary care physicians and other health care professionals.

Authors:  James R LaSalle; Rachele Berria
Journal:  J Am Osteopath Assoc       Date:  2013-02

Review 4.  What can we learn from patient-reported outcomes of insulin pen devices?

Authors:  Barbara J Anderson; Maria J Redondo
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

5.  A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study.

Authors:  H C Gerstein; J-F Yale; S B Harris; M Issa; J A Stewart; E Dempsey
Journal:  Diabet Med       Date:  2006-07       Impact factor: 4.359

6.  Diabetes patients' experiences with the implementation of insulin therapy and their perceptions of computer-assisted self-management systems for insulin therapy.

Authors:  Airin Cr Simon; Wouter T Gude; Frits Holleman; Joost Bl Hoekstra; Niels Peek
Journal:  J Med Internet Res       Date:  2014-10-23       Impact factor: 5.428

Review 7.  T2DM Self-Management via Smartphone Applications: A Systematic Review and Meta-Analysis.

Authors:  Mingxuan Cui; Xueyan Wu; Jiangfeng Mao; Xi Wang; Min Nie
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

8.  The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.

Authors:  Luigi Meneghini; Stephen L Atkin; Stephen C L Gough; Itamar Raz; Lawrence Blonde; Marina Shestakova; Stephen Bain; Thue Johansen; Kamilla Begtrup; Kåre I Birkeland
Journal:  Diabetes Care       Date:  2013-01-22       Impact factor: 19.112

9.  Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people.

Authors:  Kamlesh Khunti; Michael L Wolden; Brian Larsen Thorsted; Marc Andersen; Melanie J Davies
Journal:  Diabetes Care       Date:  2013-07-22       Impact factor: 19.112

10.  How much is too much? Outcomes in patients using high-dose insulin glargine.

Authors:  T Reid; L Gao; J Gill; A Stuhr; L Traylor; A Vlajnic; A Rhinehart
Journal:  Int J Clin Pract       Date:  2015-11-13       Impact factor: 2.503

View more
  3 in total

1.  Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial.

Authors:  Irene Hramiak; Hertzel C Gerstein; Lawrence A Leiter; Jean-François Yale; Harpreet S Bajaj; John Stewart; Marie-Josée Toutounji; Stewart B Harris
Journal:  Diabetes Obes Metab       Date:  2022-06-29       Impact factor: 6.408

2.  Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care.

Authors:  Roopa Mehta; Ronald Goldenberg; Daniel Katselnik; Louis Kuritzky
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

Review 3.  Leveraging advances in diabetes technologies in primary care: a narrative review.

Authors:  Bruce Bode; Aaron King; David Russell-Jones; Liana K Billings
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.